18,000 Shares in CVS Health Corporation $CVS Purchased by Pensionfund Sabic

Pensionfund Sabic acquired a new position in shares of CVS Health Corporation (NYSE:CVS) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 18,000 shares of the pharmacy operator’s stock, valued at approximately $1,428,000.

Other large investors have also modified their holdings of the company. Journey Strategic Wealth LLC bought a new stake in shares of CVS Health during the 2nd quarter valued at about $265,000. AlphaCore Capital LLC grew its holdings in CVS Health by 9.6% in the 2nd quarter. AlphaCore Capital LLC now owns 3,143 shares of the pharmacy operator’s stock worth $217,000 after buying an additional 274 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in CVS Health in the 2nd quarter valued at approximately $1,208,000. CreativeOne Wealth LLC raised its stake in CVS Health by 10.2% during the 2nd quarter. CreativeOne Wealth LLC now owns 7,471 shares of the pharmacy operator’s stock valued at $515,000 after acquiring an additional 693 shares in the last quarter. Finally, Insigneo Advisory Services LLC lifted its position in CVS Health by 86.9% in the second quarter. Insigneo Advisory Services LLC now owns 8,083 shares of the pharmacy operator’s stock worth $558,000 after purchasing an additional 3,759 shares during the period. Institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Friday, March 13th. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Bank of America dropped their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. Mizuho upped their price target on CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.05.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Proposed FTC settlement on insulin pricing for Caremark eases a major legal overhang — CVS said it reached a proposed agreement with FTC staff covering its Caremark PBM unit (Caremark denies wrongdoing). The resolution reduces uncertainty around potential fines or structural remedies that could have been disruptive to PBM operations, and was the main constructive catalyst for the rally. CVS reaches insulin pricing settlement with FTC
• Positive Sentiment: Analyst upgrade supports sentiment — Bernstein upgraded CVS to Outperform (price target raised to ~$94), highlighting exposure to a Medicare Advantage turnaround and improving fundamentals; upgrades can draw buying interest from institutional investors. Bernstein Upgrades CVS Health (CVS) Stock to Outperform from Market Perform
• Neutral Sentiment: Health-care sector breadth provided tailwinds — the NYSE Health Care Index rose late in the session, lifting peers and creating a supportive macro backdrop for CVS. Sector momentum likely amplified the stock’s move. Sector Update: Health Care Stocks Advance Late Afternoon
• Neutral Sentiment: Technical bounce after multi-session weakness — coverage noted CVS rising after a six-session losing streak, which can attract short-term buyers and traders looking for mean reversion. CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
• Negative Sentiment: State-level political pressure could create regulatory risk — reporting shows a Tennessee bill that would pit retail pharmacies against PBMs (potentially forcing CVS to choose between its stores and Caremark), and a local report flagged ~$479M in related spending; this raises the prospect of restrictive state laws or reputational risk. This bill could make CVS choose between its stores and its pharmacy benefit manager
• Negative Sentiment: Political/legal headline noise and potential compliance issues — coverage of CVS spending >$1M on ads to oppose the pharmacy bill and reporting that Tenn. AG says certain company texts could violate state law add short-term political and legal uncertainty that could pressure sentiment if escalated. CVS Health spends more than $1M on TV ads to block pharmacy bill Tenn. AG: CVS texts on pharmacy bill could violate state law
• Negative Sentiment: Critical articles highlight operational and valuation risks — some media pieces calling out risks in CVS’ business mix and recent share declines can reinforce cautious positioning among investors. 3 Reasons CVS is Risky and 1 Stock to Buy Instead

CVS Health Stock Up 2.1%

Shares of NYSE:CVS opened at $72.80 on Wednesday. The company has a 50 day moving average price of $77.14 and a two-hundred day moving average price of $77.81. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The company has a market capitalization of $92.61 billion, a PE ratio of 52.75, a PEG ratio of 0.74 and a beta of 0.49. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period last year, the firm posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.7%. The ex-dividend date is Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.